MARC Record from harvard_bibliographic_metadata

LEADER: 10374cam a22005414a 4500
001 011453831-X
005 20080509152538.0
008 070130s2007 dcua bf 001 0 eng
010 $a 2007004385
015 $aGBA714618$2bnb
016 7 $a101298434$2DNLM
016 7 $a013678493$2Uk
020 $a9781585623174 (pbk. : alk. paper)
020 $a1585623172 (pbk. : alk. paper)
035 0 $aocm81944018
040 $aDNLM/DLC$cDLC$dBAKER$dNLM$dUKM$dBTCTA$dC#P$dYDXCP$dNOR$dNLGGC
042 $apcc
050 00 $aRM315$b.S37 2007
060 00 $a2008 F-076
060 10 $aQV 77$bS312m 2007
082 00 $a616.89/18$222
100 1 $aSchatzberg, Alan F.
245 10 $aManual of clinical psychopharmacology /$cAlan F. Schatzberg, Jonathan O. Cole, Charles DeBattista.
250 $a6th ed.
260 $aWashington, DC :$bAmerican Psychiatric Pub.,$cc2007.
300 $axxv, 697 p. :$bill. ;$c21 cm.
504 $aIncludes bibliographical references (p. 645-646) and index.
505 00 $tPreface --$g1.$tGeneral principles of psychopharmacological treatment --$tGeneral advice --$tPractice guidelines --$tLegal, ethical, and economic issues --$tBibliography --$g2.$tDiagnosis and classifiction --$tModd disorders --$tBipolar disorders --$tDepressive disorders --$tSchizophrenia and other schizophrenia spectrum disorders --$tAnxiety disorders --$tSomatoform disorders --$tPersonality disorders --$tPsychoactive substance use disorders --$tChild and adolescent disorders --$tFDA approval of symptom reduction strategies --$tDSM-V and pharmacogenetics --$tSummary --$tBibliography --$g3.$tAntidepressants --$tHistory --$tGeneral priciples of antidepressant use --$tChoosing an antidepressant --$tDosage and administration --$tDuration of treatment --$tSelective serotonin reuptake inhibitors --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tDiscontinuation --$t5-HT₂ receptor antagonists (Trazodone and Nefazodone) --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and admdinistratin --$tDiscontinuation --
505 00 $tSelective serotonin-norepinephrine reuptake inhibitors (Venlafaxine adn Duloxetine) --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tDiscontinuation --$tCombined noradrenergic-dopaminergic antidepressant (Bupropion) --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tMirtazapine --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tNorepinephrine reuptake inhibitors : reboxetine and atomoxetine --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tDiscontinuation --$tGepirone --$tTricyclic and tetracyclic antidepressants --$tStructures --$tPharmacological effects --$tIndications --$tBlood levels --$tSide effects --$tOverdose --$tDosage and administration --$tDiscontinuation --$tMonoamine oxidase inhibitors --$tPharmacological effects --$tIndications --$tSide effects --$tOverdose --$tDrug interactions --$tDosage and administration --$tDiscontinuation --$tSelective and reversible monoamine oxidase inhibitors --$tMelatonin agonist-5-HT₂c antagonist --$tNovel antidepressants --$tBibliography --
505 00 $g4.$tAntipsychotic drugs --$gGeneral principles of antipsychotic use --$gThe$tdrugs --$tEfficacy --$tAcute antipsychotic treatment --$tEarly inpatient treatment --$tMaintenance drug therapy --$tUse in other psychiatric disorders --$tAtypical antipsychotics --$tClozapine --$tRisperidone --$tOlanzapine --$tQuetiapine --$tZipradisone --$tAripiprazole --$tStandard (typical) antipsychotics --$tSide effects --$tHaloperidol decanoate --$tOther options for treating negative symptoms --$tAlternatives to antipsychotic therapy --$tAntipsychotic drugs in development --$tBibliography --$g5.$tMood stabilizers --$tLithium --$tHistory and indications --$tPharmacological effects --$tClinical indications --$tSide effects --$tPreparations --$tDosage and administration --$tUse in pregnancy --$tLithium Information Center --$tAnticonvulsants --$tValproate --$tCarbamazepine --$tLamotrigine --$tOther anticonvulsants --$tAntipsycholtics --$tBenzodiazepines --$tCalcium channel blockers --$tOmega-3 fatty acids --$tBibliography --$g6.$tAntianxiety agents --$tBenzodiazepines --$tIndications --$tPharmacological effects --$tSubclasses --$tDosage and administration --$tWithdrawal --$tSide effects --$tOverdose --$tAntidepressants --$tAgoraphobia and panic --$tGeneralized anxiety disorder --$tSocial phobia --$tBody dysmorphic disorder --$tPosttraumatic stress disorder --$tObsessive-compulsive disorder --$tAnticonvulsants --$tAntipsychotics --$tNoradrenergic agents --$tClinical indications --$tDosage and administration --$tSide effects --
505 00 $tAntihistamines --$tBuspirone --$tBarbiturates --$tAmobarbital sodium (amytal) as a parenteral solution --$tCatatonia --$tMeprobamate --$tBibliography --$g7.$tHypnotics --$tInsomnia --$tBehavioral approaches --$tPharmacological approaches --$tBenzodiazephine hypnotics --$tNonbenzodiazephine hypnotics --$tMelatonin receptor agonist : Remelteon --$tSedative antihistamines and other nonbenzodiazepine psychoactive drugs with hypnotic properties --$tBarbiturates --$tNonbarbiturate hypnotics --$tMethaqualone --$tOver-the-counter sleeping agents --$tL-tryptophan --$tMelatonin --$tValerian extract --$tGeneral conclusions --$tBibliography --$g8.$tStimulants and other fast-acting drugs --$tAmphetamine abuse --$tUses of stimulants --$tAttention-deficit/hyperactivity disorder --$tDepression --$tAcquired immunodeficiency syndrome --$tOther medical conditions --$tDrug combinations --$tPsychosis --$tStimulant use versus abuse --$tOther fast-acting drugs --$tBibliography --
505 00 $g9.$tAugmentation strategies for treatment-resistant disorders --$tAugmentation strategies for depression --$tLithium-antidepressant combinations --$tThyroid supplement-antidepressant combinations --$tEstrogen, DHEA, and testosterone combinations with antidepressants --$tDopamine agonist-antidepressant combinations --$tMonoamine precursor-antidepressant combinations --$tSSRI combinations --$tAntipsychotic-antidepressant combinations --$tOther TCA combinations --$tAugmentation strategies for bipolar disorder --$tCombinations of two or more mood stabilizers --$tMood stabilizer-antipsychotic combinations --$tMood stabilizer-antidepressant combinations --$tMood stabilizers and omega-3 fatty acids --$tAugmentation strategies for schizophrenia --$tCombinations of two antipsychotics --$tCombinations of antidepressants and antipsychotics --$tCombinations of mood stabilizers and antipsychotics --$tOther augmentation strategies --$tBibliography --$g10.$tEmergency room treatment --$tAgitation and violence --$tDepression and suicidality --$tAcute psychotic reactions --$tMixed psychotic reactions --$tSchizophrenic, schizophreniform, and manic psychoses --$tDelirium --$tSevere anxiety --$tStupor and catatonia --$tEmergency room referrals --$tBibliography --
505 00 $g11.$tPharmacotherapy for substance use disorders --$tDrug testing --$tStimulants --$tOpiates --$tDetoxification --$tMaintenance --$tSedatives and hypnotics --$tDetoxification --$tPentobarbital tolerance test --$tBenzodiazepines --$tAlcohol --$tMaintenance treatment --$tCannabis --$tHallucinogens --$tPhencyclidine --$tBibliography --$g12.$tPharmacotherapy in special situations --$tPregnancy --$tPediatric psychopharmacology --$tStimulants --$tAntipsychotics --$tAntidepressants --$tMood stabilizers --$tAntianxiety drugs --$tGeriatric psychopharmacology --$tAntidepressants --$tHypnotics and anxiolytics --$tMood stabilizers --$tAntipsychotics --$tMedications for dementia --$tMedications for agitation --$tMental retardation --$tMedical conditions --$tPsychiatric disorders resulting from medical illness --$tPsychiatric disorders associated with nonpsychiatric drugs --$tPsychiatric disorders complicated by medical disorders --$tConclusion --$tBibliography --
505 00 $g13.$tHerbals and dietary supplements --$tSt. John's Wort (Hypericum perforatum) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tOmega-3 fatty acids --$tUses and mechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tKava (Piper methysticum) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tValerian (Valeriana officinalis) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tGinkgo (Ginkgo biloba) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tFolate and B vitamins --$tS-adenosylmethionine (SAMe) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tInositol --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --
505 00 $tDHEA (dehydroepiandrosterone) --$tUses --$tMechanism of action --$tSide effects and drug interactions --$tDosage and administration --$tBibliography --$tAppendix A : Strengths and costs of antidepressant and antipsychotic drugs --$tAppendix B : Suggested readings --$tIndex.
520 $aPocket manual on selection and prescription of appropriate drug therapies. Compatible with the DSM-IV. Additional sections added to this edition include summary tables with key information on classes of psychotropics and a chapter on herbals and dietary supplements. Chapters have been updated and revised.
650 0 $aPsychopharmacology$vHandbooks, manuals, etc.
650 0 $aPsychotropic drugs$vHandbooks, manuals, etc.
650 17 $aFarmacologie.$2gtt
650 17 $aPsychofarmaca.$2gtt
650 12 $aPsychopharmacology.
650 22 $aMental Disorders$xdrug therapy.
650 22 $aPsychotropic Drugs$xpharmacology.
655 7 $aHandbooks, manuals, etc.$2fast
700 1 $aCole, Jonathan O.
700 1 $aDeBattista, Charles.
988 $a20080501
906 $0OCLC